Research programme: sodium glucose co-transporter inhibitors - Taisho

Drug Profile

Research programme: sodium glucose co-transporter inhibitors - Taisho

Alternative Names: SGLT inhibitors - Taisho

Latest Information Update: 23 Sep 2011

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class Small molecules
  • Mechanism of Action Sodium-glucose transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 25 Jul 2007 Preclinical development is ongoing
  • 01 Nov 2005 Data presented at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD-2005) has been added to the Diabetes pharmacodynamics section
  • 06 Jul 2005 Preclinical trials in Type-2 diabetes mellitus in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top